HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tsuyoshi Takami Selected Research

VAP-cyclo protocol

6/2017CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
1/2014Serum soluble tumor necrosis factor receptor 1 level is associated with the outcome of diffuse large B-cell lymphoma patients treated with the CHOP or R-CHOP regimen.
10/2013Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
5/2012Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
2/2004Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tsuyoshi Takami Research Topics

Disease

17Neoplasms (Cancer)
04/2015 - 04/2002
16Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
10/2018 - 06/2005
6Non-Hodgkin Lymphoma (Lymphosarcoma)
10/2013 - 06/2002
4Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
12/2017 - 01/2009
4Lymphoma (Lymphomas)
10/2017 - 06/2006
3Cardiotoxicity
10/2018 - 02/2004
2T-Cell Lymphoma (Lymphoma, T Cell)
12/2017 - 01/2008
2Inflammation (Inflammations)
10/2017 - 01/2002
2B-Cell Lymphoma (Lymphoma, B Cell)
02/2012 - 04/2007
2Fibrosis (Cirrhosis)
11/2010 - 04/2008
2Glioma (Gliomas)
06/2009 - 04/2007
2Melanoma (Melanoma, Malignant)
03/2007 - 03/2005
2Experimental Melanoma
05/2006 - 03/2005
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/2018
1Carcinogenesis
10/2017
1Mucopolysaccharidoses
07/2013
1Mucopolysaccharidosis IV (Morquio Syndrome)
07/2013
1Aspiration Pneumonia
03/2013
1Contact Dermatitis (Eczema, Contact)
01/2012
1Allergic Contact Dermatitis
01/2012
1Hemangiosarcoma (Angiosarcoma)
01/2010
1Respiratory Insufficiency (Respiratory Failure)
01/2010
1Lymphadenopathy
01/2009
1Immunoproliferative Small Intestinal Disease
01/2008
1Pathologic Complete Response
01/2008
1Adenocarcinoma
04/2007
1Leukemia
04/2007
1LIG4 Syndrome
04/2007
1Neoplasm Metastasis (Metastasis)
03/2007
1Renal Cell Carcinoma (Grawitz Tumor)
03/2007
1Colonic Neoplasms (Colon Cancer)
03/2007
1Hepatocellular Carcinoma (Hepatoma)
07/2006
1Squamous Cell Carcinoma of Head and Neck
04/2006
1Virus Diseases (Viral Diseases)
02/2005
1Hepatitis B
02/2005
1Astrocytoma (Pilocytic Astrocytoma)
03/2003
1Glioblastoma (Glioblastoma Multiforme)
03/2003

Drug/Important Bio-Agent (IBA)

14Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2018 - 06/2002
14Vincristine (Oncovin)FDA LinkGeneric
10/2018 - 06/2002
13Prednisolone (Predate)FDA LinkGeneric
10/2018 - 06/2002
12Doxorubicin (Adriamycin)FDA LinkGeneric
10/2018 - 02/2004
11Rituximab (Mabthera)FDA Link
10/2018 - 10/2009
7pirarubicinIBA
10/2018 - 02/2004
7Interleukin-2 (IL2)IBA
01/2010 - 04/2004
3KynurenineIBA
12/2017 - 04/2010
3Type II Tumor Necrosis Factor ReceptorsIBA
10/2013 - 09/2006
3Interleukin-2 Receptors (IL 2 Receptor)IBA
05/2012 - 02/2005
3Monoclonal AntibodiesIBA
04/2011 - 06/2005
3Complementary DNA (cDNA)IBA
05/2006 - 04/2004
2IfosfamideFDA LinkGeneric
09/2017 - 06/2002
2Carboplatin (JM8)FDA LinkGeneric
09/2017 - 06/2002
2Methotrexate (Mexate)FDA LinkGeneric
09/2017 - 06/2002
2Etoposide (VP 16)FDA LinkGeneric
09/2017 - 06/2002
2Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA
06/2012 - 04/2011
2LipidsIBA
11/2010 - 04/2008
2Proteins (Proteins, Gene)FDA Link
01/2008 - 06/2006
2DNA (Deoxyribonucleic Acid)IBA
04/2007 - 06/2006
2ParaffinIBA
04/2006 - 03/2003
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
12/2017
1Glycoproteins (Glycoprotein)IBA
10/2017
1ProgranulinsIBA
10/2017
1MethylprednisoloneFDA LinkGeneric
09/2017
1AnthracyclinesIBA
06/2017
12- methyl- 4- carboxy- 5- hydroxy- 3,4,5,6- tetrahydropyrimidineIBA
06/2017
1ChromatinIBA
04/2015
1Keratins (Keratin)IBA
04/2015
1CollagenIBA
04/2015
1Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
01/2014
1SulfatasesIBA
07/2013
1GlycosaminoglycansIBA
07/2013
1Keratan SulfateIBA
07/2013
1Anti-Bacterial Agents (Antibiotics)IBA
03/2013
1DinitrofluorobenzeneIBA
01/2012
1Interleukin-18 (Interleukin 18)IBA
09/2011
1Prednisone (Sone)FDA LinkGeneric
04/2011
1Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
01/2011
1ChemokinesIBA
06/2009
1Chemokine ReceptorsIBA
06/2009
1Tumor Biomarkers (Tumor Markers)IBA
01/2009
1Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
09/2008
1Interleukin-13IBA
09/2008
1Transforming Growth Factor beta (TGF-beta)IBA
05/2008
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
04/2007
1DNA Ligase ATPIBA
04/2007
1Phosphates (Orthophosphate)IBA
03/2007
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2006
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
07/2006
1Fas Ligand Protein (Fas Ligand)IBA
06/2006
1Histocompatibility Antigens Class IIBA
05/2006
1SurvivinIBA
06/2005
1AntigensIBA
06/2005
1MethyltransferasesIBA
03/2003
1Messenger RNA (mRNA)IBA
03/2003

Therapy/Procedure

9Therapeutics
10/2018 - 04/2002
6Drug Therapy (Chemotherapy)
09/2017 - 06/2002
5VAP-cyclo protocol
06/2017 - 02/2004
3Aftercare (After-Treatment)
03/2013 - 01/2009
1Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)
01/2010
1Immunotherapy
04/2007
1Radiotherapy
04/2006